Accuray Incorporated
Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation t… Read more
Accuray Incorporated (ARAY) - Net Assets
Latest net assets as of December 2025: $53.42 Million USD
Based on the latest financial reports, Accuray Incorporated (ARAY) has net assets worth $53.42 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($448.01 Million) and total liabilities ($394.59 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $53.42 Million |
| % of Total Assets | 11.92% |
| Annual Growth Rate | N/A |
| 5-Year Change | 17.91% |
| 10-Year Change | 36.05% |
| Growth Volatility | 28.07 |
Accuray Incorporated - Net Assets Trend (2002–2025)
This chart illustrates how Accuray Incorporated's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Accuray Incorporated (2002–2025)
The table below shows the annual net assets of Accuray Incorporated from 2002 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $81.17 Million | +80.04% |
| 2024-06-30 | $45.08 Million | -15.98% |
| 2023-06-30 | $53.66 Million | +0.88% |
| 2022-06-30 | $53.19 Million | -22.74% |
| 2021-06-30 | $68.84 Million | +8.18% |
| 2020-06-30 | $63.63 Million | +27.60% |
| 2019-06-30 | $49.87 Million | +2.55% |
| 2018-06-30 | $48.63 Million | +4.51% |
| 2017-06-30 | $46.53 Million | -22.00% |
| 2016-06-30 | $59.66 Million | -21.27% |
| 2015-06-30 | $75.78 Million | -23.10% |
| 2014-06-30 | $98.55 Million | -7.76% |
| 2013-06-30 | $106.83 Million | -47.60% |
| 2012-06-30 | $203.87 Million | -15.17% |
| 2011-06-30 | $240.33 Million | +41.31% |
| 2010-06-30 | $170.08 Million | +10.51% |
| 2009-06-30 | $153.90 Million | +17.70% |
| 2008-06-30 | $130.76 Million | +4.24% |
| 2007-06-30 | $125.44 Million | +255.15% |
| 2006-06-30 | $-80.86 Million | -43.94% |
| 2005-06-30 | $-56.17 Million | -69.97% |
| 2003-06-30 | $-33.05 Million | -39.84% |
| 2002-06-30 | $-23.63 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Accuray Incorporated's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 51927200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $113.00K | 0.14% |
| Other Comprehensive Income | $-1.84 Million | -2.26% |
| Other Components | $602.16 Million | 741.87% |
| Total Equity | $81.17 Million | 100.00% |
Accuray Incorporated Competitors by Market Cap
The table below lists competitors of Accuray Incorporated ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SunWay Biotech Co., LTD.
TWO:1271
|
$45.04 Million |
|
Southern Rubber Industry JSC
VN:CSM
|
$45.04 Million |
|
Coxon Precise Industrial Co Ltd
TW:3607
|
$45.04 Million |
|
Barem Ambalaj Sanayi ve Ticaret a.s.
IS:BARMA
|
$45.05 Million |
|
SYN-Tech Chem & Pharm Co Ltd
TWO:1777
|
$45.00 Million |
|
DURECT CORP. DL-001
F:DC8A
|
$44.99 Million |
|
IF Bancorp Inc
NASDAQ:IROQ
|
$44.99 Million |
|
Multitude SE
LSE:0R4W
|
$44.97 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Accuray Incorporated's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 45,084,000 to 81,169,000, a change of 36,085,000 (80.0%).
- Net loss of 1,591,000 reduced equity.
- New share issuances of 1,627,000 increased equity.
- Other comprehensive income increased equity by 2,385,000.
- Other factors increased equity by 33,664,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.59 Million | -1.96% |
| Share Issuances | $1.63 Million | +2.0% |
| Other Comprehensive Income | $2.38 Million | +2.94% |
| Other Changes | $33.66 Million | +41.47% |
| Total Change | $- | 80.04% |
Book Value vs Market Value Analysis
This analysis compares Accuray Incorporated's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.50x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-06-30 | $-2.24 | $0.39 | x |
| 2003-06-30 | $-3.12 | $0.39 | x |
| 2005-06-30 | $-3.93 | $0.39 | x |
| 2006-06-30 | $-5.05 | $0.39 | x |
| 2007-06-30 | $4.08 | $0.39 | x |
| 2008-06-30 | $2.16 | $0.39 | x |
| 2009-06-30 | $2.62 | $0.39 | x |
| 2010-06-30 | $2.83 | $0.39 | x |
| 2011-06-30 | $3.82 | $0.39 | x |
| 2012-06-30 | $2.76 | $0.39 | x |
| 2013-06-30 | $1.46 | $0.39 | x |
| 2014-06-30 | $1.30 | $0.39 | x |
| 2015-06-30 | $0.97 | $0.39 | x |
| 2016-06-30 | $0.74 | $0.39 | x |
| 2017-06-30 | $0.56 | $0.39 | x |
| 2018-06-30 | $0.57 | $0.39 | x |
| 2019-06-30 | $0.57 | $0.39 | x |
| 2020-06-30 | $0.70 | $0.39 | x |
| 2021-06-30 | $0.75 | $0.39 | x |
| 2022-06-30 | $0.58 | $0.39 | x |
| 2023-06-30 | $0.57 | $0.39 | x |
| 2024-06-30 | $0.46 | $0.39 | x |
| 2025-06-30 | $0.79 | $0.39 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Accuray Incorporated utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1.96%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -0.35%
- • Asset Turnover: 0.98x
- • Equity Multiplier: 5.79x
- Recent ROE (-1.96%) is above the historical average (-21.21%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 0.00% | -29.95% | 1.62x | 0.00x | $-3.43 Million |
| 2003 | 0.00% | -584.50% | 0.08x | 0.00x | $-12.54 Million |
| 2005 | 0.00% | -112.57% | 0.26x | 0.00x | $-19.57 Million |
| 2006 | 0.00% | -63.70% | 0.38x | 0.00x | $-25.61 Million |
| 2007 | -4.48% | -4.00% | 0.42x | 2.65x | $-18.16 Million |
| 2008 | 4.12% | 2.56% | 0.71x | 2.26x | $-7.69 Million |
| 2009 | 0.40% | 0.26% | 0.85x | 1.78x | $-14.78 Million |
| 2010 | 1.67% | 1.28% | 0.84x | 1.55x | $-14.17 Million |
| 2011 | -11.61% | -12.00% | 0.49x | 1.98x | $-49.66 Million |
| 2012 | -36.83% | -17.60% | 0.86x | 2.42x | $-91.60 Million |
| 2013 | -96.62% | -32.67% | 0.66x | 4.45x | $-113.90 Million |
| 2014 | -35.97% | -9.60% | 0.75x | 5.02x | $-45.30 Million |
| 2015 | -53.06% | -10.59% | 0.81x | 6.20x | $-47.79 Million |
| 2016 | -42.75% | -6.40% | 0.85x | 7.86x | $-31.47 Million |
| 2017 | -63.57% | -7.71% | 0.94x | 8.73x | $-34.23 Million |
| 2018 | -49.14% | -5.90% | 1.07x | 7.79x | $-28.76 Million |
| 2019 | -32.94% | -3.92% | 0.96x | 8.79x | $-21.42 Million |
| 2020 | 6.01% | 1.00% | 0.78x | 7.71x | $-2.54 Million |
| 2021 | -9.17% | -1.59% | 0.83x | 6.97x | $-13.20 Million |
| 2022 | -10.05% | -1.24% | 0.91x | 8.89x | $-10.67 Million |
| 2023 | -17.29% | -2.07% | 0.93x | 8.93x | $-14.65 Million |
| 2024 | -34.48% | -3.48% | 0.95x | 10.39x | $-20.05 Million |
| 2025 | -1.96% | -0.35% | 0.98x | 5.79x | $-9.71 Million |
Industry Comparison
This section compares Accuray Incorporated's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Accuray Incorporated (ARAY) | $53.42 Million | 0.00% | 7.39x | $45.01 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |